Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novavax announces positive top-line data from dose-confirmatory phase 2 clinical trial of RSV vaccine candidate in women of childbearing age

Monday, 28 Apr 2014 04:13pm EDT 

Novavax Inc:Says positive top-line safety and immunogenicity data from its RSV-F protein nanoparticle vaccine candidate in a Phase 2 clinical trial in women of childbearing age.Randomized, blinded, placebo-controlled Phase 2 study was designed to evaluate the immunogenicity and safety of multiple formulations of Novavax' RSV-F protein nanoparticle vaccine adjuvanted with aluminum phosphate.Primary outcome of the trial was safety and immune response (measured by levels of serum IgG antibody specific for the F protein).These top-line data relate to the safety and immunogenicity over the 91-day period following first immunization and support Novavax' maternal immunization strategy. 

Company Quote

0.64 +8.44%
27 Mar 2015